The estimated Net Worth of Steve Elms is at least $45.1 Миллион dollars as of 18 March 2024. Mr. Elms owns over 461,716 units of Adma Biologics Inc stock worth over $35,775,997 and over the last 10 years he sold ADMA stock worth over $9,146,531. In addition, he makes $137,205 as Independent Chairman of the Board at Adma Biologics Inc.
Sign up
Mr. Elms ADMA stock SEC Form 4 insiders trading
Steven has made over 3 trades of the Adma Biologics Inc stock since 2021, according to the Form 4 filled with the SEC. Most recently he sold 461,716 units of ADMA stock worth $2,802,616 on 18 March 2024.
The largest trade he's ever made was buying 1,142,857 units of Adma Biologics Inc stock on 16 March 2021 worth over $2,000,000. On average, Steven trades about 82,589 units every 34 days since 2014. As of 18 March 2024 he still owns at least 2,115,671 units of Adma Biologics Inc stock.
You can see the complete history of Mr. Elms stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Steven Elms biography
Steven A. Elms serves as Independent Chairman of the Board of the Company. Mr. Elms has been a director of the Company since 2007 and is the Company’s Chairman of the Board. Mr. Elms serves as a Managing Partner at Aisling Capital, which he joined in 2000. Previously, he was a Principal in the Life Sciences Investment Banking Group of Hambrecht & Quist. During his five years at Hambrecht & Quist, Mr. Elms was involved in over 60 financing and merger and acquisition transactions, helping clients raise in excess of $3.3 billion in capital. Prior to joining Hambrecht & Quist, Mr. Elms traded mortgage-backed securities at Donaldson, Lufkin & Jenrette. His previous healthcare sector experience includes over two years as a pharmaceutical sales representative for Marion Laboratories and two years as a consultant for The Wilkerson Group. Mr. Elms currently serves on the board of directors of Zosano Pharma Corp. (Nasdaq: ZSAN) and previously served on the board of directors of Loxo Oncology, Inc. (Nasdaq: LOXO), Cidara Therapeutics, Inc. (Nasdaq: CDTX) and Pernix Therapeutics Holdings, Inc. (OTCMKTS: PTXTQ) within the past five years. Mr. Elms received a B.A. in Human Biology from Stanford University and an M.B.A. from Kellogg Graduate School of Management at Northwestern University. Mr. Elms was chosen to serve on the Board because of his valuable experience in the investment banking industry, particularly with respect to strategic and financing transactions.
What is the salary of Steven Elms?
As the Independent Chairman of the Board of Adma Biologics Inc, the total compensation of Steven Elms at Adma Biologics Inc is $137,205. There are 6 executives at Adma Biologics Inc getting paid more, with Adam Grossman having the highest compensation of $1,702,020.
How old is Steven Elms?
Steven Elms is 56, he's been the Independent Chairman of the Board of Adma Biologics Inc since . There are 7 older and 5 younger executives at Adma Biologics Inc. The oldest executive at Adma Biologics Inc is Dr. James Mond, 74, who is the Exec. VP, Chief Scientific Officer & Chief Medical Officer.
What's Steven Elms's mailing address?
Steve's mailing address filed with the SEC is 489 5TH AVENUE, 10TH FLOOR, NEW YORK, NY, 10017.
Insiders trading at Adma Biologics Inc
Over the last 11 years, insiders at Adma Biologics Inc have traded over $43,950,328 worth of Adma Biologics Inc stock and bought 17,510,201 units worth $56,736,742 . The most active insiders traders include Advisors Llcperceptive Life..., Ag Biotest Pharmaceuticals ... и Divestiture Trust Biotest. On average, Adma Biologics Inc executives and independent directors trade stock every 34 days with the average trade being worth of $7,366,858. The most recent stock trade was executed by Lawrence P. Guiheen on 9 September 2024, trading 9,000 units of ADMA stock currently worth $97,200.
What does Adma Biologics Inc do?
adma is a late-stage biopharmaceutical company that develops, manufactures and intends to commercialize specialty plasma-based biologics for the treatment and prevention of primary immune deficiency disease (pidd) and certain infectious diseases. adma's mission is to develop and commercialize plasma-derived, human immune globulins targeted to niche patient populations for the treatment and prevention of certain infectious diseases. the target patient populations include immune-compromised individuals who suffer from an underlying immune deficiency disease, or who may be immune-compromised for medical reasons. adma’s lead product candidate, ri-002, has completed a phase iii clinical trial in patients with pidd and has met the primary endpoint. a bla for ri-002 was accepted by the fda on september 18, 2015. the company has received u.s. patent 9,107,906. for more information, please visit the company's website at www.admabiologics.com.
What does Adma Biologics Inc's logo look like?
Complete history of Mr. Elms stock trades at Adma Biologics Inc, Cidara Therapeutics Inc, Zosano Pharma Corp и Marker Therapeutics
Adma Biologics Inc executives and stock owners
Adma Biologics Inc executives and other stock owners filed with the SEC include:
-
Adam Grossman,
President, Chief Executive Officer, Co-Founder, Director -
James Mond,
Executive Vice President, Chief Scientific Officer, Chief Medical Officer -
Adam S. Grossman,
Co-Founder, Pres, CEO & Director -
Brian Lenz,
Chief Financial Officer, Executive Vice President -
Dr. James Mond,
Exec. VP, Chief Scientific Officer & Chief Medical Officer -
Brian Lenz CPA, CPA,
Exec. VP, CFO & GM of ADMA BioCenters -
Jerrold Grossman,
Vice Chairman of the Board, Co-Founder -
Steven Elms,
Independent Chairman of the Board -
Bryant Fong,
Independent Director -
Lawrence Guiheen,
Independent Director -
Dr. Jerrold B. Grossman D.P.S., Ph.D.,
Co-Founder & Vice Chairman -
Dr. Jerrold B. Grossman Ph.D., D.P.S.,
Co-Founder & Vice Chairman -
Martha Demski,
Independent Director -
Cyndi Tolman,
Sr. VP of Plasma Services -
Neal C. Fitzpatrick,
VP of Sales -
Michael Goldstein,
Sr. Director & Gen. Counsel -
Dr. Gene A. Wetzstein BCOP, Pharm.D.,
Exec. Director & Head of Scientific Engagement -
Drew Pantello,
VP of Marketing & Corp. Devel. -
Michael Least,
VP of Sales & Commercial Operations -
Kaitlin Kestenberg,
VP of Compliance, Project Management & Clinical Operations -
Skyler Bloom,
Director of Investor Relations & Corp. Strategy -
Kim Tripodo,
Exec. Director & Head of Human Resource and Admin. Operations -
Eric I Richman,
Director -
Dov A Md Goldstein,
Director -
Ag Biotest Pharmaceuticals ...,
-
Young Kwon,
-
Alison Cecily Finger,
-
Divestiture Trust Biotest,
10% owner -
Steve Elms,
-
Advisors Llcperceptive Life...,
-
Brad L. Tade,
CFO and Treasurer -
Kaitlin M. Kestenberg Messina,
COO and SVP, Compliance